The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chronic Eosinophilic Leukemia

Clonal proliferation of eosinophils with end organ damage

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Chronic Eosinophilic Leukemia?

Chronic eosinophilic leukemia includes the FIP1L1 PDGFRA fusion variant which is highly responsive to tyrosine kinase inhibition and a not otherwise specified group with persistent eosinophilia above one and a half thousand per microliter for at least six months and evidence of clonality or excess myeloblasts under twenty percent.

Workup excludes secondary causes such as parasitic infection, allergy, drug reaction, and lymphoid driven hypereosinophilic syndrome through stool studies, IgE testing, T cell receptor rearrangement, immunophenotyping for aberrant lymphocytes, and flow cytometry. Bone marrow biopsy assesses cellularity, fibrosis, eosinophil precursor proportion, and karyotype with FISH for PDGFRA, PDGFRB, and FGFR1 rearrangements.

Therapy follows molecular profile: FIP1L1 PDGFRA positive cases enter durable remission with low dose imatinib at one hundred milligrams daily, PDGFRB rearrangement responds to imatinib at higher doses, FGFR1 disease is aggressive and may require allogeneic transplant. Idiopathic eosinophilic leukemia is treated with corticosteroids, hydroxyurea, interferon alpha, or mepolizumab depending on organ involvement and response.

Symptoms

Cardiac fibrosis and restrictive cardiomyopathy
Pulmonary infiltrates and cough
Skin pruritus and erythematous rash
Neurological symptoms with peripheral neuropathy
Splenomegaly with abdominal discomfort

Risk Factors

FIP1L1 PDGFRA fusion in some cases
PDGFRB or FGFR1 rearrangement rare
Idiopathic clonal proliferation
Adult age and male predominance
Underlying myeloproliferative spectrum

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When persistent eosinophilia exceeds threshold
  • When end organ damage develops
  • When secondary causes are excluded
  • When molecular testing is needed
  • When tyrosine kinase inhibitor candidacy is assessed

Treatment Methods

01
Imatinib for FIP1L1 PDGFRA fusion
02
Imatinib higher dose for PDGFRB rearrangement
03
Allogeneic transplant for FGFR1 disease
04
Corticosteroids for symptomatic idiopathic disease
05
Hydroxyurea for cytoreduction
06
Interferon alpha or mepolizumab in select cases
07
Cardiac surveillance with echocardiography

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.